drugset / Trial / NCT01220726

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726

Phase 3 Completed 30 enrolled Weill Medical College of Cornell University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:

Timeline

Start
2009-06
Primary completion
2011-06
Completion
2012-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 200 iu Other

Indications